Natural Products: Back In Vogue?
This article was originally published in Start Up
Several small biotechs are heading back to nature, spotting promising drug targets in exotic plants, sea creatures, and venomous animals, even as Big Pharma and venture capital remain skeptical of the approach.
You may also be interested in...
With funds and firms closing, a new reality awaits those who survive until the next economic upswing. Some of the elements are already in place, such as VCs' willingness to take capped returns and exits via risk-sharing contingency-based acquisitions. The emphasis on capital efficiency may change the types of companies VCs can afford to back, and corporate funds are now a vital part of biotech venture, especially in the early stages.
Eli Lilly announced August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent.
With big Phase III failures heating debate about the amyloid hypothesis, small biotechs must convince investors that their early research is pointed in the right direction, and larger ones must design clinical trials with care. We profile four Alzheimer's-focused start-ups in this issue: AlzProtect, Axerion Therapeutics, Cognition Therapuetics and Galantos Pharma.